Abstract
Knee osteoarthritis is a chronic, progressive, degenerative disease that most commonly presents in individuals over the age of 50 years with symptoms of pain, swelling, stiffness, crepitus and functional limitations. It is characterized by the progressive loss of hyaline cartilage resulting in joint space narrowing and bony changes. Furthermore, the synovial fluid contained within osteoarthritic joints, of which hyaluronan is a major protective constituent, undergoes a degenerative process. This has led to a treatment modality to replace hyaluronan, which is known as viscosupplementation. Viscosupplementation use has been supported by numerous studies and several meta-analyses to be safe and effective in ameliorating the pain and functional limitations associated with knee osteoarthritis. However, up until fairly recently, viscosupplementation was provided through weekly intra-articular injections over a course of 3–5 weeks. Synvisc-One™ (Genzyme Biosurgery Corporation, MA, USA) is one example of a newly ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
